Prime Medicine wins arbitration ruling against Beam over PM647 development candidate
An arbitration tribunal issued a final award on July 6, 2026, declaring that Prime Medicine's PM647 candidate for Alpha-1 Antitrypsin Deficiency is within the agreement's Field and that the company did not breach its 2019 agreement with Beam Therapeutics. The tribunal denied Beam's requests for damages and injunctive relief and denied the remaining claims by both parties. The ruling removes a breach claim tied to a key development candidate, though the filing gives no financial figures.
Key points
- Final Award received July 6, 2026 from the arbitration tribunal in proceedings with Beam Therapeutics
- Tribunal declared PM647, targeting Alpha-1 Antitrypsin Deficiency, is within the agreement's Field
- Tribunal denied Beam's requests for damages and injunctive relief and denied remaining claims by both parties
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.